Regeneron beats results estimates on demand for eczema treatment, eye drug
Oct 31 (Reuters) -U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea.
Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff competition from rivals, including Roche's ROG.S Vabysmo.
Swiss drugmaker Rochereaffirmed its full-year profit forecast while beating quarterly estimates for sales last week, banking on strong demand for Vabysmo.
Total U.S. net sales of Eylea, jointly developed with Bayer AG BAYGn.DE, rose 3% to $1.54 billion, including $392 millionfrom the higher, 8-milligram dose version of the drug.
The high-dose version of the eye disease drug was launched in August 2023 and allows for longer intervals between injections for patients.
Regeneron's total revenue of $3.72 billionbeat expectations of $3.67 billion, according to data compiled by LSEG.
The drugmaker's anti-inflammatory drug Dupixent posted sales of $3.82 billion, beating estimatesof $3.78 billion. French partner Sanofi SASY.PA records Dupixent sales and profits are split equally between the companies.
Dupixent is currently approved to treat six disease types including asthma, a skin condition called atopic dermatitis and most recently as an add-on treatment for chronic obstructive pulmonary disease.
The company reported an adjusted profit of $12.46per share for the quarter, above estimatesof $11.69 per share.
Reporting by Christy Santhosh in Bengaluru; Editing by Devika Syamnath
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
